SAN DIEGO, June 4, 2019 /PRNewswire/ -- Neurocrine
Biosciences, Inc. (NASDAQ: NBIX) will present at the Goldman Sachs
40th Annual Global Healthcare Conference at 10:00 a.m. PT (1:00 p.m.
ET) on Tuesday, June 11, 2019,
in Rancho Palos Verdes, Calif.
Kevin Gorman, Chief Executive
Officer, and Matt Abernethy, Chief
Financial Officer, of Neurocrine Biosciences will present at the
conference.
The live presentation will be webcast and may be accessed on the
Company's website under Investors at www.neurocrine.com. A replay
of the presentation will be available on the website approximately
one hour after the conclusion of the event and will be archived for
approximately one month.
About Neurocrine Biosciences
Neurocrine Biosciences
(Nasdaq: NBIX) is a neuroscience-focused, biopharmaceutical company
with more than 25 years of experience discovering and developing
life-changing treatments for people with serious, challenging and
under-addressed neurological, endocrine and psychiatric
disorders. The company's diverse portfolio includes
FDA-approved treatments for tardive dyskinesia and endometriosis*
and clinical development programs in multiple therapeutic areas
including Parkinson's disease, congenital adrenal hyperplasia and
uterine fibroids*. Headquartered in San
Diego, Neurocrine Biosciences specializes in targeting and
interrupting disease-causing mechanisms involving the
interconnected pathways of the nervous and endocrine
systems. For more information, visit neurocrine.com, and
follow the company on LinkedIn. (*in
collaboration with AbbVie)
View original content to download
multimedia:http://www.prnewswire.com/news-releases/neurocrine-biosciences-to-present-at-goldman-sachs-40th-annual-global-healthcare-conference-300861785.html
SOURCE Neurocrine Biosciences, Inc.